Open Access

MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer

  • Authors:
    • Danni Chen
    • Lei Cao
    • Xiaojie Wang
  • View Affiliations

  • Published online on: June 12, 2019     https://doi.org/10.3892/or.2019.7199
  • Pages: 679-687
  • Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Tumor metastasis is the leading cause of mortality in patients with advanced ovarian cancer. Myelin protein zero like 1 (MPZL1) is a transmembrane glycoprotein that promotes migration of hepatocellular carcinoma cells and is involved in extracellular matrix‑induced signal transduction. However, the functional role of MPZL1 in ovarian cancer has not been well elucidated. The present study conducted western blotting, phase‑contrast imaging and immunohistochemistry to reveal the functions of MPZL1 in ovarian cancer. The present study demonstrated that the expression levels of MPZL1 were associated with malignant features of ovarian cancer. Furthermore, overexpression of MPZL1 significantly promoted cell proliferation, migration and invasion of ovarian cancer cells. Conversely, MPZL1 depletion by short hairpin RNA inhibited migration and invasion of ovarian cancer cells. In addition, this study demonstrated that phosphorylation of Src kinase was increased upon MPZL1 overexpression. Additionally, phosphorylation and activation of pro‑metastatic proteins p130 and cortactin were induced by phosphorylated Src kinase. Collectively, these findings indicated that MPZL1 may be a novel pro‑metastatic gene, which promotes tumor cell proliferation and migration through Src‑mediated phosphorylation of p130 and cortactin in ovarian cancer.

References

1 

Marcus CS, Maxwell GL, Darcy KM, Hamilton CA and McGuire WP: Current approaches and challenges in managing and monitoring treatment response in ovarian cancer. J Cancer. 5:25–30. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA and Cottrill HM: A brief review of the management of platinum- resistant-platinum-refractory ovarian cancer. Med Oncol. 34:1032017. View Article : Google Scholar : PubMed/NCBI

3 

Walker JL, Powell CB, Chen Lm, Carter J, Bae Jump VL, Parker LP, Borowsky ME and Gibb RK: Society of gynecologic oncology recommendations for the prevention of ovarian cancer. Cancer. 121:2108–2120. 2015. View Article : Google Scholar : PubMed/NCBI

4 

Matz M, Coleman MP, Carreira H, Salmerón D, Chirlaque MD and Allemani C; CONCORD Working Group, : Worldwide comparison of ovarian cancer survival: Histological group and stage at diagnosis (CONCORD-2). Gynecol Oncol. 144:396–404. 2017. View Article : Google Scholar : PubMed/NCBI

5 

Jiménez-Sánchez A, Memon D, Pourpe S, Veeraraghavan H, Li Y, Vargas HA, Gill MB, Park KJ, Zivanovic O, Konner J, et al: Heterogeneous tumor-immune microenvironments among differentially growing metastases in an ovarian cancer patient. Cell. 170:927–938. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Hillman RT, Lu KH and Futreal PA: A novel genomic rearrangement signature to predict poor survival among women with high grade serous ovarian cancer. J Clin Oncol. 35 (Suppl 15):S55092017. View Article : Google Scholar

7 

Lengyel E: Ovarian cancer development and metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI

8 

Bast RC, Hennessy B and Mills GB: The biology of ovarian cancer: New opportunities for translation. Nat Rev Cancer. 9:415–428. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Naora H and Montell DJ: Ovarian cancer metastasis: Integrating insights from disparate model organisms. Nat Rev Cancer. 5:355–366. 2005. View Article : Google Scholar : PubMed/NCBI

10 

Luo Z, Wang Q, Lau WB, Lau B, Xu L, Zhao L, Yang H, Feng M, Xuan Y, Yang Y, et al: Tumor microenvironment: The culprit for ovarian cancer metastasis? Cancer Lett. 377:174–182. 2016. View Article : Google Scholar : PubMed/NCBI

11 

He G, Liu X, Qin W, Chen Q, Wang X, Yang Y, Zhou J, Xu Y, Gu N, Feng G, et al: MPZL1/PZR, a novel candidate predisposing schizophrenia in Han Chinese. Mol Psychiatry. 11:748–751. 2006. View Article : Google Scholar : PubMed/NCBI

12 

Beigbeder A, Chartier FJ and Bisson N: MPZL1 forms a signalling complex with GRB2 adaptor and PTPN11 phosphatase in HER2-positive breast cancer cells. Sci Rep. 7:115142017. View Article : Google Scholar : PubMed/NCBI

13 

Zhao R, Guerrah A, Tang H and Zhao ZJ: Cell surface glycoprotein PZR is a major mediator of concanavalin A-induced cell signaling. J Biol Chem. 277:7882–7888. 2002. View Article : Google Scholar : PubMed/NCBI

14 

Fonseca NA, He Y, Greger L, Brazma A and Zhang Z: Comprehensive genome and transcriptome analysis reveals genetic basis for gene fusions in cancer. bioRxiv. 1486842017.

15 

Zhao ZJ and Zhao R: Purification and cloning of PZR, a binding protein and putative physiological substrate of tyrosine phosphatase SHP-2. J Biol Chem. 273:29367–29372. 1998. View Article : Google Scholar : PubMed/NCBI

16 

Playford MP and Schaller MD: The interplay between Src and integrins in normal and tumor biology. Oncogene. 23:7928–7946. 2004. View Article : Google Scholar : PubMed/NCBI

17 

Wang L, Dong P, Zhang Y, Yang M, Chen Y and Tian BL: Prognostic validation of the updated 8th edition Tumor-Node- Metastasis classification by the Union for international cancer control: Survival analyses of 307 patients with surgically treated gallbladder carcinoma. Oncol Lett. 16:4427–4433. 2018.PubMed/NCBI

18 

Uhlen M, Oksvold P, Fagerberg L, Lundberg E, Jonasson K, Forsberg M, Zwahlen M, Kampf C, Wester K, Hober S, et al: Towards a knowledge-based human protein atlas. Nature Biotechnol. 28:1248–1250. 2010. View Article : Google Scholar

19 

Dai Y, Qi L, Zhang X, Li Y, Chen M and Zu X: CrkI and p130(Cas) complex regulates the migration and invasion of prostate cancer cells. Cell Biochem Funct. 29:625–629. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Padhye A, Ungewiss C, Fradette JJ, Rodriguez BL, Albritton JL, Miller JS and Gibbons DL: A novel ex vivo tumor system identifies Src-mediated invasion and metastasis in mesenchymal tumor cells in non-small cell lung cancer. Sci Rep. 9:48192019. View Article : Google Scholar : PubMed/NCBI

21 

Wu H, Jing X, Cheng X, He Y, Hu L, Wu H, Ye F and Zhao R: Asporin enhances colorectal cancer metastasis through activating the EGFR/src/cortactin signaling pathway. Oncotarget. 7:73402–73413. 2016.PubMed/NCBI

22 

Zhang XH, Wang Q, Gerald W, Hudis CA, Norton L, Smid M, Foekens JA and Massagué J: Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer cell. 16:67–78. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Summy JM and Gallick GE: Src family kinases in tumor progression and metastasis. Cancer Metastasis Rev. 22:337–358. 2003. View Article : Google Scholar : PubMed/NCBI

24 

Huang J, Asawa T, Takato T and Sakai R: Cooperative roles of fyn and cortactin in cell migration of metastatic murine melanoma. J Biol Chem. 278:48367–48376. 2003. View Article : Google Scholar : PubMed/NCBI

25 

Brábek J, Constancio SS, Siesser PF, Shin NY, Pozzi A and Hanks SK: Crk-associated substrate tyrosine phosphorylation sites are critical for invasion and metastasis of SRC-transformed cells. Mol Cancer Res. 3:307–315. 2005. View Article : Google Scholar : PubMed/NCBI

26 

Parsons SJ and Parsons JT: Src family kinases, key regulators of signal transduction. Oncogene. 23:7906–7909. 2004. View Article : Google Scholar : PubMed/NCBI

27 

Jia D, Jing Y, Zhang Z, Liu L, Ding J, Zhao F, Ge C, Wang Q, Chen T, Yao M, et al: Amplification of MPZL1/PZR promotes tumor cell migration through src-mediated phosphorylation of cortactin in hepatocellular carcinoma. Cell Res. 24:204–217. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Zhao R and Zhao ZJ: Dissecting the interaction of SHP-2 with PZR, an immunoglobulin family protein containing immunoreceptor tyrosine-based inhibitory motifs. J Biol Chem. 275:5453–5459. 2000. View Article : Google Scholar : PubMed/NCBI

29 

Yeh YT, Dai HY and Chien CY: Amplification of MPZL1/PZR gene in hepatocellular carcinoma. Hepatobiliary surg Nutr. 3:87–90. 2014.PubMed/NCBI

30 

Giannoni E, Buricchi F, Raugei G, Ramponi G and Chiarugi P: Intracellular reactive oxygen species activate Src tyrosine kinase during cell adhesion and anchorage-dependent cell growth. Mol Cell Biol. 25:6391–6403. 2005. View Article : Google Scholar : PubMed/NCBI

31 

Shor AC, Keschman EA, Lee FY, Muro-Cacho C, Letson GD, Trent JC, Pledger WJ and Jove R: Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer Res. 67:2800–2808. 2007. View Article : Google Scholar : PubMed/NCBI

32 

Yu H and Jove R: The STATs of cancer-new molecular targets come of age. Nat Rev Cancer. 4:97–105. 2004. View Article : Google Scholar : PubMed/NCBI

33 

Mitra SK and Schlaepfer DD: Integrin-regulated FAK-src signaling in normal and cancer cells. Curr Opin Cell Biol. 18:516–523. 2006. View Article : Google Scholar : PubMed/NCBI

34 

Vuori K and Ruoslahti E: Tyrosine phosphorylation of p130Cas and cortactin accompanies integrin-mediated cell adhesion to extracellular matrix. J Biol Chem. 270:22259–22262. 1995. View Article : Google Scholar : PubMed/NCBI

35 

Ammer AG, Kelley LC, Hayes KE, Evans JV, Lopez-Skinner LA, Martin KH, Frederick B, Rothschild BL, Raben D, Elvin P, et al: Saracatinib impairs head and neck squamous cell carcinoma invasion by disrupting invadopodia function. J Cancer Sci Ther. 1:52–61. 2009. View Article : Google Scholar : PubMed/NCBI

36 

Agerer F, Lux S, Michel A, Rohde M, Ohlsen K and Hauck CR: Cellular invasion by Staphylococcus aureus reveals a functional link between focal adhesion kinase and cortactin in integrin-mediated internalisation. J Cell Sci. 118:2189–2200. 2005. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

August 2019
Volume 42 Issue 2

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Chen, D., Cao, L., & Wang, X. (2019). MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer. Oncology Reports, 42, 679-687. https://doi.org/10.3892/or.2019.7199
MLA
Chen, D., Cao, L., Wang, X."MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer". Oncology Reports 42.2 (2019): 679-687.
Chicago
Chen, D., Cao, L., Wang, X."MPZL1 promotes tumor cell proliferation and migration via activation of Src kinase in ovarian cancer". Oncology Reports 42, no. 2 (2019): 679-687. https://doi.org/10.3892/or.2019.7199